Innate Pharma S.A. Sponsored ADR Total non-current liabilities

Total non-current liabilities of IPHA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total non-current liabilities growth rates and interactive chart.


Highlights and Quick Summary

  • Total non-current liabilities for the quarter ending December 30, 2020 was $121 Million (a 155.88% increase compared to previous quarter)
  • Year-over-year quarterly Total non-current liabilities increased by 40.33%
  • Annual Total non-current liabilities for 2020 was $121 Million (a 73.96% increase from previous year)
  • Annual Total non-current liabilities for 2019 was $69.6 Million (a -32.47% decrease from previous year)
Visit stockrow.com/IPHA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total non-current liabilities of Innate Pharma S.A. Sponsored ADR

Most recent Total non-current liabilitiesof IPHA including historical data for past 10 years.

Interactive Chart of Total non-current liabilities of Innate Pharma S.A. Sponsored ADR

Innate Pharma S.A. Sponsored ADR Total non-current liabilities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $121.04 $47.3 $121.04
2019 $69.58 $86.25 $69.58
2018 $103.03 $103.03

Business Profile of Innate Pharma S.A. Sponsored ADR

Sector: Healthcare
Industry: Biotechnology
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.